We're adding to our position in a stock that just got some big support from Wall Street.
Shortly after the bell rings, we will buy 300 shares of Bristol Myers Squibb at approximately $56.50. Following the deal,…
Bristol-Myers Squibb Co.
We want to increase our ownership of a portfolio stock that just increased its dividend.
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Our newest portfolio stocks pulled back from their recent 52-week high, so we're buying more
We are buying 300 shares of Bristol-Myers Squibb at approximately $58 each. Following Wednesday's trade, Jim Cramer's Charitable Trust will…
Wall Street mulls data on weight-loss drug Amgen
The Amgen logo is displayed outside of Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama |…
Bristol Myers Squibb (BMY) Q3 2024 Results
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, USA, on Wednesday, December 27, 2023.…
10 things to watch in the stock market on Friday, including a bullish call on Best Buy
Ten Things to Watch for Friday, September 27 1. The S&P 500 was pointing to a slightly higher open on…
FDA approves Bristol Myers Squibb's schizophrenia drug
Bristol Myers Squibb's Cobenfy drug Courtesy: Bristol Myers Squibb The Food and Drug Administration on Thursday approved Bristol-Myers SquibbCobenfy, the…
AstraZeneca and drugmakers release promising cancer data
Attendees walk through the lobby of the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg…
This promising cancer treatment could represent a $25 billion market opportunity
Skynesher | E+ | fake images Big Pharma is betting billions on a promising class of cancer treatments that some…
Stocks set to move as this corner of the cancer therapy market heats up
Much attention has been paid lately to a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy…